Nifedipine, a new antihypertensive with rapid action

Guazzi, Maurizio D.; Olivari, Maria Teresa; Polese, A; Fiorentini, Cesare; Magrini, Fabio; Moruzzi, P

doi:10.1002/cpt1977225part1528

Cited by 247 publications

(50 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Esper et al (1975) and Linke (1975) (Muracakami et al, 1972;Guazzi et al, 1977;Simonsen & Nitter-Hauge 1978); and it is possible that this increase may counteract their hypotensive effect.…”

Section: Discussionmentioning

confidence: 99%

Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine.

Iliopoulou¹,

Turner²,

Warrington³

1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The acute cardiovascular response to nicardipine was investigated using non invasive techniques in normal subjects. 2 In six subjects, i.v. nicardipine in an increasing dose (0.5-20 mg) was compared with saline, under double-blind conditions. A dose related increase in heart rate and fall in blood pressure were found. Pre-ejection period (PEP) and PEP/left ventricular ejection time (LVET) ratio of the systolic time intervals were shortened in a clearly dose related manner. Total electromechanical systole index (QS2 I) was decreased and LVET index prolonged. 3 In four subjects increasing oral doses (10-40 mg) of nicardipine, administered in a randomized double-blind placebo control design, demonstrated the same pattern, marked changes being found with the 40 mg dose.4 Comparison with nifedipine in a double-blind-placebo controlled balanced trial in six subjects confirmed that 40 mg nicardipine and 20 mg nifedipine exhibited similar effects. Maximum response was reached between 0.5 and 1.5 h, and changes in some cardiovascular variables were still evident at 3 h.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine.

Iliopoulou¹,

Turner²,

Warrington³

1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that this drug exerts a prompt and marked hypotensive effect when administered to hypertensive patients (Murakami et al, 1972;Aoki et al, 1976;Guazzi et al 1977;Pedersen and Mikkelsen 1978;Imai et al 1980) and the drug has been accepted as a critical therapeutic for several forms of hypertension (Guazzi et al 1983;Massie et al 1984; Muhller et …”

mentioning

confidence: 99%

Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients.

Imai

Abe

Sasaki

et al. 1986

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

In patients with essential hypertension, the pharmacokinetics of nifedipine in 2 forms (capsule, 10 mg nifedipine dissolved in an organic solvent ; slow release tablet, 20 mg nifedipine) and their pharmacodynamic effectiveness on arterial pressure were studied. The maximum plasma concentration was higher and achieved more rapidly after application of the capsule than after the retard tablet (p <0.01). The plasma half-time of nifedipine in the capsule was shorter than that in the retard tablet (p <0.05). The absorption rate of nifedipine from the capsule tended to be larger than that from the retard tablet. Plasma concentrations of nifedipine, measured 12 hr after the dosing of the retard tablet during chronic treatment, were not different from those after the acute administration of the retard tablet, suggesting that no accumulation of nifedipine occurs. The capsule of nifedipine elicited prompt and profound hypotension with short duration, while the retard tablet produced a hypotensive effect with relatively slow onset and long duration. Arterial pressure reduction was maintained throughout the day using 12 hourly dose of the retard tablet. During the chronic treatment the maximum hypotensive effect was observed 4 weeks after the start of treatment. Twelve hourly administration of the retard tablet is a convenient regimen for the long-term control of mild to severe essential hypertension.nifedipine ; slow release form ; conventional form ; antihypertensive therapy ; essential hypertension Nifedipine is a potent vasodilator, which relaxes vascular smooth muscle probably by its inhibitory effect on the transmembrane influx of calcium (Fleckenstein et al. 1972 ). It has been demonstrated that this drug exerts a prompt and marked hypotensive effect when administered to hypertensive patients (Murakami et al, 1972;Aoki et al, 1976;Guazzi et al. 1977;Pedersen and Mikkelsen 1978;Imai et al. 1980) and the drug has been accepted as a critical therapeutic for several forms of hypertension (Guazzi et al. 1983;Massie et al. 1984; Muhller et

show abstract

“…The haemodynamic profile of amlodipine is also in keeping with other reports of dihydropyridine calcium channel blocking agents in clinical practice. Nifedipine has been shown to reduce peripheral vascular resistance and increase heart rate and cardiac output (Guazzi et al, 1977;Murakami et al, 1972;Simonsen & Nitter-Hauge, 1978). Similar profiles for nicardipine have been shown by Rousseau et al (1984b), Visser et al (1985) and Lambert et al (1985) and for nisoldipine by Vogt et al (1980Vogt et al ( , 1983.…”

Section: Discussionmentioning

confidence: 99%

Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.

Silke

Verma

Zezulka

et al. 1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The haemodynamic and radionuclide effects of a new long-acting slow-calcium channel blocking agent, amlodipine, were evaluated in 32 patients with coronary artery disease. 2 Haemodynamic measurements in 24 patients were made at rest and 10 to 15 min after 20 mg i.v. amlodipine. Amlodipine significantly reduced systemic arterial blood pressure and vascular resistance index with an increased heart rate and augmented cardiac index. Cardiac stroke volume index rose and stroke work fell without change in pulmonary artery occluded pressure (PAOP). 3 The exercise effects were determined by comparison of measurements during 4 min of supine bicycle exercise at a fixed workload before and after drug treatment. During dynamic exercise, amlodipine reduced systemic arterial pressure and vascular resistance index. Exercise cardiac index, stroke volume index and heart rate were higher. The left ventricular filling pressure was significantly reduced. 4 Radionuclide parameters were studied in 16 patients at rest and on exercise; ejection fraction was unaltered following amlodipine. 5 Pre-therapy haemodynamic values correlated with response following amlodipine for resting mean blood pressure, systemic vascular resistance and exercise PAOP. 6 Thus, the immediate impact of amlodipine in stable coronary artery disease was to reduce left ventricular afterload and thereby improve cardiac pumping performance.

show abstract

Nifedipine, a new antihypertensive with rapid action

Cited by 247 publications

References 4 publications

Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine.

Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine.

Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients.

Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.

Contact Info

Product

Resources

About